Date: 2015-01-23
Type of information: Loan
Company: Bind Therapeutics (USA - MA)
Investors: Hercules Technology Growth Capital (USA - CA)
Amount: $15 million
Funding type: loan
Planned used:
Others: * On January 23, 2015, Bind Therapeutics announced that it has entered into an amendment of its existing credit facility from Hercules Technology III, L.P., an affiliate of Hercules Technology Growth Capital. Under the amendment, the company borrowed an additional $15 million in growth capital, less the repayment of the outstanding balance on BIND's existing term loan facility of approximately $3 million. In connection with the amendment, Bind issued Hercules warrants to purchase shares of BIND common stock totaling three percent of the additional amount raised.
Therapeutic area: Cancer - Oncology